Autoimmune diagnostics: the technology, the strategy and the clinical governance

Immunologic Research

Volumn 61, Issue 1-2, 2015, Pages 126-134

  Bizzaro, Nicola ^a   Tozzoli, Renato ^b   Villalta, Danilo ^b  

^a Ospedale San Antonio   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Autoimmunology; Clinical governance; Diagnostics; Immunoassay; Laboratory autoimmunologist; Strategy

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOMATION; DIAGNOSIS; HEALTH CARE QUALITY; HUMAN; IMMUNOFLUORESCENCE; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOID VASCULITIS; AUTOIMMUNE DISEASES; DIAGNOSTIC USE; IMMUNOASSAY; IMMUNOLOGY; LABORATORY AUTOMATION; PROCEDURES; STANDARDS;

AUTOANTIBODY;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOMATION, LABORATORY; CLINICAL GOVERNANCE; HUMANS; IMMUNOASSAY;

EID: 84925535741     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8587-z     Document Type: Article

References (61)

1. Nakamura RM, Bylund DJ. Factors influencing changes in the clinical immunology laboratory. Clin Chem. 1994;40:2193–204.
2. Tozzoli R, Bizzaro N. The clinical autoimmunologist and the laboratory autoimmunologist: the two sides of the coin. Autoimmun Rev. 2012;11:766–70.
3. Tomar R. Total laboratory automation and diagnostic immunology. Clin Diagn Lab Immunol. 1999;6:293–4.
4. Bock JL. The new era of automated immunoassay. Am J Clin Pathol. 2000;113:628–46.
5. Wu AHB. A selected history and future of immunoassay development and applications in clinical chemistry. Clin Chim Acta. 2006;369:119–24.
6. Ekins RP. Ligand assays: from electrophoresis to miniaturized microarrays. Clin Chem. 1998;44:2015–30.
7. Tozzoli R, Bonaguri C, Melegari A, Antico A, Bassetti D, Bizzaro N. Current state of diagnostic technologies in the autoimmunology laboratory. Clin Chem Lab Med. 2013;51:129–38.
8. Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F, et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol. 2002;117:316–24.
9. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010;69:1420–2.
10. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73:17–23.
11. Tozzoli R, Antico A, Porcelli B, Bassetti D. Automation in indirect immunofluorescence testing: a new step in the evolution of the autoimmunology laboratory. Autoimmun Highlights. 2012;3:59–65.
12. Meroni PL, Bizzaro N, Cavazzana I, Borghi MO, Tincani A. Automated test of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med. 2014;12:38.
13. Bizzaro N, Antico A, Platzgummer S, Tonutti E, Bassetti D, Pesente F, et al. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun Rev. 2013;13:292–8.
14. Wang C, Wu J, Zong C, Xu J, Ju HX. Chemiluminescent immunoassay and its applications. Chin J Anal Chem. 2012;40:3–10.
15. Tozzoli R, Villalta D. Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. Autoimmun Rev. 2014;13:59–63.
16. Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum. 2007;56:1736–44.
17. Kostantinov KN, Tzamaloukas A, Rubin RL. Detection of autoantibodies in a point-of-care rheumatology setting. Autoimmun Highlights. 2013;4:55–61.
18. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. GRADE: grading quality of evidence and strengths of recommendations for diagnostic tests and strategy. Br Med J. 2008;336:1106–10.
19. Bizzaro N, Wiik A. Appropriateness in anti-nuclear antibody testing: from clinical request to strategic laboratory practice. Clin Exp Rheumatol. 2004;22:349–55.
20. Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47:434–44.
21. Tampoia M, Brescia V, Fontana A, Zucano A, Morrone LF, Pansini N. Application of a combined protocol for rational request and utilization of antibody assays improves clinical diagnostic efficiency in autoimmune rheumatic disease. Arch Pathol Lab Med. 2007;131:112–6.
22. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA–DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52:3433–8.
23. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA–DR3 and the shared epitope alleles. Arthritis Rheum. 2005;52:3813–8.
24. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GMC, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. PNAS. 2011;108:17372–7.
25. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum. 2008;58:3009–19.
26. Zhao J, Zhao Y, He J, Jia R, Li Z. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol. 2008;35:969–74.
27. Strollo R, Ponchel F, Malmström V, Rizzo P, Bombardieri M, Wenham CY, et al. Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis Rheum. 2013;65:1702–12.
28. Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, Rosen A. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med. 2013;5:186ra65.
29. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol. 1999;111:507–13.
30. Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, et al. Addendum to the international consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies. Am J Clin Pathol. 2003;120:312–8.
31. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
32. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, Pierangeli SS. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies. Arthritis Rheum. 2012;64:1–10.
33. Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A, Ruffatti A. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev. 2013;12:832–4.
34. Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436–42.
35. Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D, et al. Overcoming a “probable” diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. Clin Rev Allergy Immunol. 2012;42:288–97.
36. Tonutti E, Visentini D, Picierno A, Bizzaro N, Villalta D, Tozzoli R, et al. Diagnostic efficacy of the ELISA test for the detection of deamidated anti-gliadin peptide antibodies in the diagnosis and monitoring of celiac disease. J Clin Lab Anal. 2009;23:165–71.
37. Tonutti E, Bizzaro N. Diagnosis and classification of celiac disease and gluten sensitivity. Autoimmun Rev. 2014;13:472–6.
38. Maglio M, Tosco A, Paparo F, Auricchio R, Granata V, Colicchio B, et al. Serum and intestinal celiac disease-associated antibodies in children with celiac disease younger than 2 years of age. J Pediatr Gastroenterol Nutr. 2010;50:43–8.
39. Volta U, Fabbri A, Parisi C. Deamidated gliadin peptide antibodies as a routine test for celiac disease: a prospective analysis. J Clin Gastroenterol. 2010;44:186–90.
40. Brusca I, Carroccio A, Tonutti E, Villalta D, Tozzoli R, Barrale M, et al. The old and new tests for celiac disease: which is the best test combination to diagnose celiac disease in pediatric patients? Clin Chem Lab Med. 2011;50:111–7.
41. Bizzaro N, Tozzoli R, Villalta D, Fabris M, Tonutti E. Cutting-edge issues in celiac disease and in gluten intolerance. Clin Rev Allergy Immunol. 2012;42:279–87.
42. Villalta D, Alessio MG, Tampoia M, Tonutti E, Brusca I, Bagnasco M, et al. Diagnostic accuracy of IgA anti-tissue transglutaminase antibody assays in celiac disease patients with selective IgA deficiency. Ann N Y Acad Sci. 2007;1109:212–20.
43. Villalta D, Tonutti E, Prause C, Koletzko S, Uhlig HH, Vermeersch P, et al. IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA deficiency. Clin Chem. 2010;56:464–8.
44. Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136–60.
45. Department of Health. The new NHS: modern, dependable. London: Stationery Office; 1997.
46. Trenti T, Canali C, Scognamiglio A. Clinical governance and evidence-based laboratory medicine. Clin Chem Lab Med. 2006;44:724–32.
47. Lippi G. Governance of preanalytical variability: travelling the right path to the bright side of the moon? Chim Clin Acta. 2009;404:32–6.
48. Wiik AS. Appropriateness of autoantibody testing in clinical medicine. Clin Chim Acta. 2003;333:177–80.
49. Wiik AS, Bizzaro N. Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases. Autoimmun Highlights. 2012;3:35–49.
50. Wiik AS, Gordon TP, Kavanaugh AF, Lahita RG, Reeves W, van Venrooij WJ, et al. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum. 2004;51:291–8.
51. Srivastava R, Bartlett WA, Kennedy IM, Hiney A, Fletcher C, Murphy MJ. Reflex and reflective testing: efficiency and effectiveness of adding on laboratory tests. Ann Clin Biochem. 2010;47:223–7.
52. Stinton LM, Fritzler MJ. A Clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. Autoimmun Rev. 2007;7:77–84.
53. Sciacovelli L, Secchiero S, Zardo L, Zaninotto M, Plebani M. External quality assessment: an effective tool for clinical governance in laboratory medicine. Clin Chem Lab Med. 2006;44:740–9.
54. Plebani M. Harmonization in laboratory medicine: the complete picture. Clin Chem Lab Med. 2013;51:741–5.
55. Kairisto V, Hanninen KP, Leino A, Pulkki K, Peltola O, Nanto V, et al. Generation of reference values for cardiac enzymes from hospital admission laboratory data. Eur J Clin Chem Clin Biochem. 1994;32:789–96.
56. Tozzoli R, Giavarina D, Villalta D, Soffiati G, Bizzaro N. Definition of reference limits for autoantibodies to thyroid peroxidase and thyroglobulin in a large population of outpatients using an indirect method based on current data. Arch Pathol Lab Med. 2008;132:1924–8.
57. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev. 2009;8:543–8.
58. Bizzaro N, Morozzi G. A proposed model for effective collaboration between rheumatologists and clinical pathologists for the diagnosis of autoimmune rheumatic diseases. Rheumatol Int. 2009;29:849–51.
59. Barth JH. The role of clinical audit. In: Price CP, Christenson RH, editors. Evidence-based laboratory medicine. Washington, DC: AACC Press; 2003. p. 209–24.
60. Fritzler MJ. Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent. Autoimmun Highlights. 2012;3:51–8.
61. Plebani M. Appropriateness in program for continuous quality improvement in clinical laboratories. Clin Chim Acta. 2003;333:131–9.